{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T20:20:51Z","timestamp":1789935651425,"version":"4.0.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:00:00Z","timestamp":1589673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:00:00Z","timestamp":1589673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00277-020-04069-4","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T20:02:31Z","timestamp":1589659351000},"page":"1441-1451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Modern management of splenomegaly in patients with myelofibrosis"],"prefix":"10.1007","volume":"99","author":[{"given":"Douglas","family":"Tremblay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bakst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kremyanskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,17]]},"reference":[{"issue":"1","key":"4069_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","volume":"61","author":"RA Mesa","year":"1999","unstructured":"Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A (1999) Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 61(1):10\u201315","journal-title":"Am J Hematol"},{"issue":"9","key":"4069_CR2","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, M\u00fcllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 27(9):1874\u20131881","journal-title":"Leukemia."},{"issue":"3","key":"4069_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","volume":"88","author":"B Dupriez","year":"1996","unstructured":"Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 88(3):1013\u20131018","journal-title":"Blood."},{"issue":"1","key":"4069_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1365-2141.1990.tb02609.x","volume":"75","author":"G Visani","year":"1990","unstructured":"Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, Gianni L, Zuffa E, Aloe Spiriti MA, Latagliata R, Pileri S, Magrini U, Gugliotta L, Morra E, Bernasconi C, Mandelli F, Tura S (1990) Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 75(1):4\u20139","journal-title":"Br J Haematol"},{"key":"4069_CR5","first-page":"3294046","volume":"2019","author":"D Tremblay","year":"2019","unstructured":"Tremblay D, Putra J, Vogel A et al (2019) The implications of liver biopsy results in patients with myeloproliferative neoplasms being treated with ruxolitinib. Case Rep Hematol 2019:3294046","journal-title":"Case Rep Hematol"},{"issue":"7","key":"4069_CR6","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1007\/s10620-013-3018-x","volume":"59","author":"JE Mayer","year":"2014","unstructured":"Mayer JE, Schiano TD, Fiel MI, Hoffman R, Mascarenhas JO (2014) An association of myeloproliferative neoplasms and obliterative portal venopathy. Dig Dis Sci 59(7):1638\u20131641","journal-title":"Dig Dis Sci"},{"issue":"9","key":"4069_CR7","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.clml.2016.06.007","volume":"16","author":"D Aruch","year":"2016","unstructured":"Aruch D, Schwartz M, Mascarenhas J, Kremyanskaya M, Newsom C, Hoffman R (2016) Continued role of splenectomy in the management of patients with myelofibrosis. Clin Lymphoma Myeloma Leuk 16(9):e133\u2013e137","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"4069_CR8","first-page":"182","volume":"64","author":"M Nores","year":"1998","unstructured":"Nores M, Phillips EH, Morgenstern L, Hiatt JR (1998) The clinical spectrum of splenic infarction. Am Surg 64(2):182\u2013188","journal-title":"Am Surg"},{"key":"4069_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. BMC Cancer 16:167","journal-title":"BMC Cancer"},{"issue":"4","key":"4069_CR10","doi-asserted-by":"publisher","first-page":"8281","DOI":"10.4081\/hr.2019.8281","volume":"11","author":"V Accurso","year":"2019","unstructured":"Accurso V, Santoro M, Raso S, Contrino AD, Casimiro P, Piazza FD, Perez A, Russo A, Siragusa S (2019) Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: a single center study. Hematol Rep 11(4):8281","journal-title":"Hematol Rep"},{"issue":"10","key":"4069_CR11","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1038\/bcj.2011.36","volume":"1","author":"F Cervantes","year":"2011","unstructured":"Cervantes F (2011) How I treat splenomegaly in myelofibrosis. Blood Cancer J 1(10):e37","journal-title":"Blood Cancer J"},{"issue":"4","key":"4069_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29(4):392\u2013397","journal-title":"J Clin Oncol"},{"issue":"7","key":"4069_CR13","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/jum.14506","volume":"37","author":"T Cessford","year":"2018","unstructured":"Cessford T, Meneilly GS, Arishenkoff S, Eddy C, Chen LYC, Kim DJ, Ma IWY (2018) Comparing physical examination with sonographic versions of the same examination techniques for splenomegaly. J Ultrasound Med 37(7):1621\u20131629","journal-title":"J Ultrasound Med"},{"issue":"1","key":"4069_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/imj.1953.2.1.78","volume":"2","author":"CR Blackburn","year":"1953","unstructured":"Blackburn CR (1953) On the clinical detection of enlargement of the spleen. Australas Ann Med 2(1):78\u201380","journal-title":"Australas Ann Med"},{"issue":"1","key":"4069_CR15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1148\/radiol.2015150887","volume":"279","author":"KU Chow","year":"2016","unstructured":"Chow KU, Luxembourg B, Seifried E, Bonig H (2016) Spleen size is significantly influenced by body height and sex: establishment of normal values for spleen size at US with a cohort of 1200 healthy individuals. Radiology. 279(1):306\u2013313","journal-title":"Radiology."},{"issue":"3","key":"4069_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.11622\/smedj.2015040","volume":"56","author":"T Vancauwenberghe","year":"2015","unstructured":"Vancauwenberghe T, Snoeckx A, Vanbeckevoort D, Dymarkowski S, Vanhoenacker FM (2015) Imaging of the spleen: what the clinician needs to know. Singap Med J 56(3):133\u2013144","journal-title":"Singap Med J"},{"issue":"9","key":"4069_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807","journal-title":"N Engl J Med"},{"issue":"9","key":"4069_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798","journal-title":"N Engl J Med"},{"issue":"5","key":"4069_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A (2015) Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 1(5):643\u2013651","journal-title":"JAMA Oncol"},{"issue":"7","key":"4069_CR20","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA (2017) Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 4(7):e317\u2013e324","journal-title":"Lancet Haematol"},{"issue":"3","key":"4069_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/ejh.13005","volume":"100","author":"L Masarova","year":"2018","unstructured":"Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S (2018) Significance of thrombocytopenia in patients with primary and postessential thrombocythemia\/polycythemia vera myelofibrosis. Eur J Haematol 100(3):257\u2013263","journal-title":"Eur J Haematol"},{"issue":"25","key":"4069_CR22","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ, al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H, COMFORT-II investigators (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 122(25):4047\u20134053","journal-title":"Blood."},{"issue":"1","key":"4069_CR23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P, Dong T, Gopalakrishna P, Gupta V (2017) Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 10(1):156","journal-title":"J Hematol Oncol"},{"issue":"9","key":"4069_CR24","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","volume":"130","author":"KJ Newberry","year":"2017","unstructured":"Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S (2017) Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 130(9):1125\u20131131","journal-title":"Blood."},{"issue":"5","key":"4069_CR25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/01926230600867743","volume":"34","author":"MF Cesta","year":"2006","unstructured":"Cesta MF (2006) Normal structure, function, and histology of the spleen. Toxicol Pathol 34(5):455\u2013465","journal-title":"Toxicol Pathol"},{"issue":"1 Suppl 1","key":"4069_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0037-1963(00)90113-6","volume":"37","author":"A Chadburn","year":"2000","unstructured":"Chadburn A (2000) The spleen: anatomy and anatomical function. Semin Hematol 37(1 Suppl 1):13\u201321","journal-title":"Semin Hematol"},{"issue":"10","key":"4069_CR27","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1182\/bloodadvances.2017015073","volume":"2","author":"J Qiu","year":"2018","unstructured":"Qiu J, Salama ME, Hu CS, Li Y, Wang X, Hoffman R (2018) The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Adv 2(10):1130\u20131145","journal-title":"Blood Adv"},{"issue":"4","key":"4069_CR28","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.4049\/jimmunol.134.4.2310","volume":"134","author":"PJ Buckley","year":"1985","unstructured":"Buckley PJ, Dickson SA, Walker WS (1985) Human splenic sinusoidal lining cells express antigens associated with monocytes, macrophages, endothelial cells, and T lymphocytes. J Immunol 134(4):2310\u20132315","journal-title":"J Immunol"},{"issue":"2","key":"4069_CR29","first-page":"613","volume":"7","author":"EE Schmidt","year":"1993","unstructured":"Schmidt EE, MacDonald IC, Groom AC (1993) Comparative aspects of splenic microcirculatory pathways in mammals: the region bordering the white pulp. Scanning Microsc 7(2):613\u2013628","journal-title":"Scanning Microsc"},{"key":"4069_CR30","doi-asserted-by":"crossref","unstructured":"Song MK, Park BB, Uhm JE (2018) Understanding splenomegaly in myelofibrosis: association with molecular pathogenesis. Int J Mol Sci 19(3):898. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5877759\/","DOI":"10.3390\/ijms19030898"},{"issue":"7579","key":"4069_CR31","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature15530","volume":"527","author":"CN Inra","year":"2015","unstructured":"Inra CN, Zhou BO, Acar M, Murphy MM, Richardson J, Zhao Z, Morrison SJ (2015) A perisinusoidal niche for extramedullary haematopoiesis in the spleen. Nature. 527(7579):466\u2013471","journal-title":"Nature."},{"issue":"5","key":"4069_CR32","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/j.1365-2141.2004.04829.x","volume":"124","author":"G Barosi","year":"2004","unstructured":"Barosi G, Rosti V, Massa M et al (2004) Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 124(5):618\u2013625","journal-title":"Br J Haematol"},{"issue":"2","key":"4069_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.exphem.2007.10.001","volume":"36","author":"AR Migliaccio","year":"2008","unstructured":"Migliaccio AR, Martelli F, Verrucci M, Migliaccio G, Vannucchi AM, Ni H, Xu M, Jiang Y, Nakamoto B, Papayannopoulou T, Hoffman R (2008) Altered SDF-1\/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol 36(2):158\u2013171","journal-title":"Exp Hematol"},{"issue":"7","key":"4069_CR34","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/ni813","volume":"3","author":"I Petit","year":"2002","unstructured":"Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, Arenzana-Seisdedos F, Fujii N, Sandbank J, Zipori D, Lapidot T (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3(7):687\u2013694","journal-title":"Nat Immunol"},{"issue":"4","key":"4069_CR35","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/PAT.0b013e3283613dbf","volume":"45","author":"Y Miwa","year":"2013","unstructured":"Miwa Y, Hayashi T, Suzuki S, Abe S, Onishi I, Kirimura S, Kitagawa M, Kurata M (2013) Up-regulated expression of CXCL12 in human spleens with extramedullary haematopoiesis. Pathology. 45(4):408\u2013416","journal-title":"Pathology."},{"issue":"8","key":"4069_CR36","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1158\/0008-5472.CAN-09-3977","volume":"70","author":"SY Cho","year":"2010","unstructured":"Cho SY, Xu M, Roboz J, Lu M, Mascarenhas J, Hoffman R (2010) The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res 70(8):3402\u20133410","journal-title":"Cancer Res"},{"issue":"33","key":"4069_CR37","doi-asserted-by":"publisher","first-page":"54082","DOI":"10.18632\/oncotarget.10789","volume":"8","author":"H Abdelouahab","year":"2017","unstructured":"Abdelouahab H, Zhang Y, Wittner M, Oishi S, Fujii N, Besancenot R, Plo I, Ribrag V, Solary E, Vainchenker W, Barosi G, Louache F (2017) CXCL12\/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. Oncotarget. 8(33):54082\u201354095","journal-title":"Oncotarget."},{"issue":"12","key":"4069_CR38","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","volume":"110","author":"G Barosi","year":"2007","unstructured":"Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, Massa M, Rosti V, Campanelli R, Villani L, Viarengo G, Gattoni E, Gerli G, Specchia G, Tinelli C, Rambaldi A, Barbui T (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 110(12):4030\u20134036","journal-title":"Blood."},{"issue":"2","key":"4069_CR39","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jcp.22228","volume":"225","author":"M Verrucci","year":"2010","unstructured":"Verrucci M, Pancrazzi A, Aracil M, Martelli F, Guglielmelli P, Zingariello M, Ghinassi B, D'Amore E, Jimeno J, Vannucchi AM, Migliaccio AR (2010) CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin. J Cell Physiol 225(2):490\u2013499","journal-title":"J Cell Physiol"},{"issue":"12","key":"4069_CR40","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","volume":"89","author":"A Martinez-Trillos","year":"2010","unstructured":"Martinez-Trillos A, Gaya A, Maffioli M et al (2010) Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 89(12):1233\u20131237","journal-title":"Ann Hematol"},{"issue":"6","key":"4069_CR41","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1182\/blood.V97.6.1896","volume":"97","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Elliot MA, Yoon SY et al (2001) Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood. 97(6):1896\u20131897","journal-title":"Blood."},{"issue":"3","key":"4069_CR42","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1046\/j.0007-1048.2001.03331.x","volume":"116","author":"MC Petti","year":"2002","unstructured":"Petti MC, Latagliata R, Spadea T, Spadea A, Montefusco E, Aloe Spiriti MA, Avvisati G, Breccia M, Pescarmona E, Mandelli F (2002) Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 116(3):576\u2013581","journal-title":"Br J Haematol"},{"issue":"7","key":"4069_CR43","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","volume":"101","author":"RA Mesa","year":"2003","unstructured":"Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A (2003) A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 101(7):2534\u20132541","journal-title":"Blood."},{"issue":"22","key":"4069_CR44","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1182\/blood-2010-05-287417","volume":"116","author":"RA Mesa","year":"2010","unstructured":"Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, Rowe JM, Tefferi A, Tallman MS (2010) Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 116(22):4436\u20134438","journal-title":"Blood."},{"key":"4069_CR45","unstructured":"United States Food and Drug Administration. JAKAFI (Ruxolitinib) Label. 2011"},{"issue":"1","key":"4069_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10(1):55","journal-title":"J Hematol Oncol"},{"issue":"8","key":"4069_CR47","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ et al (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 30(8):1701\u20131707","journal-title":"Leukemia."},{"issue":"12","key":"4069_CR48","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117\u20131127","journal-title":"N Engl J Med"},{"issue":"9","key":"4069_CR49","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","volume":"100","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S, on behalf of the COMFORT Investigators (2015) A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 100(9):1139\u20131145","journal-title":"Haematologica."},{"issue":"5","key":"4069_CR50","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1053\/j.gastro.2016.08.059","volume":"157","author":"HK Tan","year":"2019","unstructured":"Tan HK, Leow WQ, Chang PE (2019) Ruxolitinib for the treatment of portal hypertension in a patient with primary myelofibrosis. Gastroenterology. 157(5):e26\u2013e27","journal-title":"Gastroenterology."},{"key":"4069_CR51","unstructured":"FDA approves treatment for patients with rare bone marrow disorder [press release]. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-patients-rare-bone-marrow-disorder2019. Accessed 15 Mar 2020"},{"issue":"34","key":"4069_CR52","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J (2017) SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol 35(34):3844\u20133850","journal-title":"J Clin Oncol"},{"issue":"2","key":"4069_CR53","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S (2018) Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol 5(2):e73\u2013e81","journal-title":"Lancet Haematol"},{"issue":"5","key":"4069_CR54","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","volume":"4","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN (2017) Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 4(5):e225\u2013e236","journal-title":"Lancet Haematol."},{"key":"4069_CR55","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S (2018) Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol 4:652\u2013659","journal-title":"JAMA Oncol"},{"issue":"Supplement_1","key":"4069_CR56","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2019-129293","volume":"134","author":"AT Gerds","year":"2019","unstructured":"Gerds AT, Savona MR, Scott BL et al (2019) Results of PAC203: a randomized phase 2 dose-finding study and determination of the recommended dose of pacritinib. Blood 134(Supplement_1):667\u2013667","journal-title":"Blood"},{"issue":"19","key":"4069_CR57","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1182\/blood-2014-02-558015","volume":"124","author":"X Wang","year":"2014","unstructured":"Wang X, Ye F, Tripodi J, Hu CS, Qiu J, Najfeld V, Novak J, Li Y, Rampal R, Hoffman R (2014) JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood. 124(19):2987\u20132995","journal-title":"Blood."},{"issue":"19","key":"4069_CR58","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1182\/blood-2014-09-600635","volume":"124","author":"SW Lane","year":"2014","unstructured":"Lane SW, Mullally A (2014) Hit the spleen, JAK! Blood. 124(19):2898\u20132900","journal-title":"Blood."},{"issue":"1","key":"4069_CR59","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/bjh.12948","volume":"167","author":"M Kremyanskaya","year":"2014","unstructured":"Kremyanskaya M, Mascarenhas J, Rampal R, Hoffman R (2014) Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis. Br J Haematol 167(1):144\u2013146","journal-title":"Br J Haematol"},{"issue":"4","key":"4069_CR60","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ccell.2018.03.024","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, de Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, Roberts J, Witkin M, Rapaport F, Teruya-Feldstein J, Qi J, Rampal R, Bernstein BE, Bradner JE, Levine RL (2018) Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell 33(4):785\u2013787","journal-title":"Cancer Cell"},{"key":"4069_CR61","doi-asserted-by":"crossref","unstructured":"Mascarenhas J, Kremyanskaya M, Hoffman R, et al. MANIFEST, a phase 2 study of CPI-0610, a bromodomain and extraterminal domain inhibitor (BETi), as monotherapy or \u201cadd-on\u201d to ruxolitinib, in patients with refractory or intolerant advanced myelofibrosis. Paper presented at: American Society of Hematology. 2019; Orlando.","DOI":"10.1182\/blood-2019-127119"},{"key":"4069_CR62","doi-asserted-by":"crossref","unstructured":"Harrison C, Patriarca A, Mascarenhas J, et al. Preliminary report of MANIFEST, a phase 2 study of CPI-0610, a bromodomain and extraterminal domain inhibitor (beti), in combination with ruxolitinib, in JAK inhibitor (JAKi) treatment na\u00efve myelofibrosis patients. Paper presented at: American Society of Hematology. 2019; Orlando.","DOI":"10.1182\/blood-2019-128211"},{"issue":"Supplement_1","key":"4069_CR63","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1182\/blood-2019-130158","volume":"134","author":"CN Harrison","year":"2019","unstructured":"Harrison CN, Garcia JS, Mesa RA et al (2019) Results from a phase 2 study of navitoclax in combination with ruxolitinib in patients with primary or secondary myelofibrosis. Blood 134(Supplement_1):671\u2013671","journal-title":"Blood"},{"issue":"Supplement_1","key":"4069_CR64","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood-2019-127661","volume":"134","author":"RK Rampal","year":"2019","unstructured":"Rampal RK, Verstovsek S, Devlin SM et al (2019) Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: a phase II study. Blood 134(Supplement_1):4163\u20134163","journal-title":"Blood"},{"key":"4069_CR65","unstructured":"Sorensen AL, Mikkelsen SU, Knudsen TA et al (2019) Ruxolitinib and interferon-alpha2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31879329"},{"issue":"2","key":"4069_CR66","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cncr.22021","volume":"107","author":"RA Mesa","year":"2006","unstructured":"Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A (2006) Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 107(2):361\u2013370","journal-title":"Cancer."},{"issue":"6","key":"4069_CR67","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1097\/SLA.0b013e318275496a","volume":"257","author":"KM Musallam","year":"2013","unstructured":"Musallam KM, Khalife M, Sfeir PM, Faraj W, Safadi B, Abi Saad GS, Abiad F, Hallal A, Alwan MB, Peyvandi F, Jamali FR (2013) Postoperative outcomes after laparoscopic splenectomy compared with open splenectomy. Ann Surg 257(6):1116\u20131123","journal-title":"Ann Surg"},{"issue":"26","key":"4069_CR68","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","volume":"114","author":"N Kroger","year":"2009","unstructured":"Kroger N, Holler E, Kobbe G et al (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 114(26):5264\u20135270","journal-title":"Blood."},{"issue":"6","key":"4069_CR69","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.bbmt.2017.03.002","volume":"23","author":"M Robin","year":"2017","unstructured":"Robin M, Zine M, Chevret S, Meignin V, Munoz-Bongrand N, Moatti H, Xhaard A, Sicre de Fontbrune F, Peffault de Latour R, Sarfati E, Soci\u00e9 G (2017) The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 23(6):958\u2013964","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4069_CR70","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/bjs5.1","volume":"1","author":"J Lemaire","year":"2017","unstructured":"Lemaire J, Rosiere A, Bertrand C, Bihin B, Donckier JE, Michel LA (2017) Surgery for massive splenomegaly. BJS Open 1(1):11\u201317","journal-title":"BJS Open"},{"issue":"1","key":"4069_CR71","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/10428194.2013.794269","volume":"55","author":"FP Santos","year":"2014","unstructured":"Santos FP, Tam CS, Kantarjian H et al (2014) Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma 55(1):121\u2013127","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"4069_CR72","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","volume":"95","author":"A Tefferi","year":"2000","unstructured":"Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 95(7):2226\u20132233","journal-title":"Blood."},{"issue":"4","key":"4069_CR73","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMcp1314291","volume":"371","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Schaffner W (2014) Clinical practice. Care of the asplenic patient. N Engl J Med 371(4):349\u2013356","journal-title":"N Engl J Med"},{"key":"4069_CR74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ctrv.2016.11.016","volume":"53","author":"NG Zaorsky","year":"2017","unstructured":"Zaorsky NG, Williams GR, Barta SK, Esnaola NF, Kropf PL, Hayes SB, Meyer JE (2017) Splenic irradiation for splenomegaly: a systematic review. Cancer Treat Rev 53:47\u201352","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"4069_CR75","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1046\/j.1365-2141.1998.00998.x","volume":"103","author":"MA Elliott","year":"1998","unstructured":"Elliott MA, Chen MG, Silverstein MN, Tefferi A (1998) Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 103(2):505\u2013511","journal-title":"Br J Haematol"},{"issue":"9","key":"4069_CR76","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ajh.21799","volume":"85","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Brown P, Neben-Wittich M, Tobin R, Tefferi A (2010) Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy. Am J Hematol 85(9):715\u2013716","journal-title":"Am J Hematol"},{"issue":"2","key":"4069_CR77","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12032-019-1245-5","volume":"36","author":"G Helbig","year":"2019","unstructured":"Helbig G, Wieczorkiewicz-Kabut A, Markiewicz M, Krzemie\u0144 H, W\u00f3jciak M, Bia\u0142as K, Kopera M, Rzenno E, Wo\u017aniczka K, Kopi\u0144ska A, Grygoruk-Wi\u015bniowska I, Kocl\u0119ga A (2019) Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis. Med Oncol 36(2):16","journal-title":"Med Oncol"},{"issue":"4","key":"4069_CR78","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/00004424-197307000-00054","volume":"8","author":"FE Maddison","year":"1973","unstructured":"Maddison FE (1973) Embolic therapy of hypersplenism. Investig Radiol 8(4):280\u2013281","journal-title":"Investig Radiol"},{"issue":"5","key":"4069_CR79","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2214\/ajr.132.5.777","volume":"132","author":"DG Spigos","year":"1979","unstructured":"Spigos DG, Jonasson O, Mozes M, Capek V (1979) Partial splenic embolization in the treatment of hypersplenism. AJR Am J Roentgenol 132(5):777\u2013782","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"4069_CR80","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1007\/s00268-009-0095-2","volume":"33","author":"MA Amin","year":"2009","unstructured":"Amin MA, el-Gendy MM, Dawoud IE, Shoma A, Negm AM, Amer TA (2009) Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients. World J Surg 33(8):1702\u20131710","journal-title":"World J Surg"},{"issue":"6","key":"4069_CR81","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1097\/00005373-199806000-00013","volume":"44","author":"KA Davis","year":"1998","unstructured":"Davis KA, Fabian TC, Croce MA, Gavant ML, Flick PA, Minard G, Kudsk KA, Pritchard FE (1998) Improved success in nonoperative management of blunt splenic injuries: embolization of splenic artery pseudoaneurysms. J Trauma 44(6):1008\u20131013 discussion 1013-1005","journal-title":"J Trauma"},{"key":"4069_CR82","doi-asserted-by":"crossref","unstructured":"Kis B, Mills M, Smith J et al (2019) Partial splenic artery embolization in 35 cancer patients: results of a single institution retrospective study. J Vasc Interv Radiol 31(4):584\u2013591. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31471193","DOI":"10.1016\/j.jvir.2019.05.031"},{"issue":"3","key":"4069_CR83","first-page":"197","volume":"9","author":"K Iwase","year":"1999","unstructured":"Iwase K, Higaki J, Mikata S, Tanaka Y, Yoshikawa M, Hori S, Osuga K, Kosugi S, Tamaki T, Kamiike W (1999) Laparoscopically assisted splenectomy following preoperative splenic artery embolization using contour emboli for myelofibrosis with massive splenomegaly. Surg Laparosc Endosc Percutan Tech 9(3):197\u2013202","journal-title":"Surg Laparosc Endosc Percutan Tech"},{"issue":"8","key":"4069_CR84","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1258\/ar.2012.110639","volume":"53","author":"JJ Gu","year":"2012","unstructured":"Gu JJ, He XH, Li WT, Ji J, Peng WJ, Li GD, Wang SP, Xu LC (2012) Safety and efficacy of splenic artery coil embolization for hypersplenism in liver cirrhosis. Acta Radiol 53(8):862\u2013867","journal-title":"Acta Radiol"},{"issue":"5","key":"4069_CR85","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2214\/AJR.10.4401","volume":"195","author":"CF Gonsalves","year":"2010","unstructured":"Gonsalves CF, Mitchell EP, Brown DB (2010) Management of hypersplenism by partial splenic embolization with ethylene vinyl alcohol copolymer. AJR Am J Roentgenol 195(5):1241\u20131244","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"4069_CR86","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4329\/wjr.v6.i5.160","volume":"6","author":"TA Hadduck","year":"2014","unstructured":"Hadduck TA, McWilliams JP (2014) Partial splenic artery embolization in cirrhotic patients. World J Radiol 6(5):160\u2013168","journal-title":"World J Radiol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04069-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04069-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04069-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T02:04:06Z","timestamp":1696125846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04069-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,17]]},"references-count":86,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4069"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04069-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,17]]},"assertion":[{"value":"25 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.K. receives research funding from Incyte, Celgene, Constellation, Protagonist.: Research Funding; La Jolla. R.H receives research funding from Dompe, Novartis, Janssen, Scholar Rock, Summer Road, Elstar, and Merus. J.M. has received research funding paid to the institution from Incyte, CTI Biopharma, Janssen, Promedior, Roche, Merck, Kartos, Novartis, Merus, and Arog. Honorarium from Incyte, Roche, Celgene, Prelude and Constellation. The remaining authors declare that they have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}